Data from the Impassion031 trial showed that, after a brief decline in health-related QoL in the atezolizumab and control arms, the burden of treatment eased and then remained similar through follow-up.
Medscape Medical News
Data from the Impassion031 trial showed that, after a brief decline in health-related QoL in the atezolizumab and control arms, the burden of treatment eased and then remained similar through follow-up.
Medscape Medical News